Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 1, 2011, Pages 50-62

  Kandula, Praveen ^a   Dobre, Mirela ^b,c   Schold, Jesse D ^d   Schreiber Jr , Martin J ^d   Mehrotra, Rajnish ^e,f   Navaneethan, Sankar D ^d  

^a INDIANA UNIVERSITY   (United States)

^b Huron Hospital   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE;

ARTICLE; CHRONIC KIDNEY DISEASE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; META ANALYSIS; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

CALCIUM; CHRONIC DISEASE; DIETARY SUPPLEMENTS; FIBROBLAST GROWTH FACTORS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHORUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D;

EID: 79251474745     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03940510     Document Type: Article

References (57)

1. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
2. Ginde AA, Liu MC, Camargo CA Jr: Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 169: 626-632, 2009
3. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM: Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-1033, 2005
4. Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R: Clinical measures identify vitamin D Deficiency in dialysis. Clin J Am Soc Nephrol 5: 460-467, 2010
5. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extrarenal production of calcitriol in chronic renal failure. Kidney Int 34: 368-375, 1988
6. Artaza JN, Mehrotra R, Norris KC: Vitamin D and cardiovascular system. Clin J Am Soc Nephrol 4: 1515-1522, 2009
7. Mehrotra R, Kermah DA, Salusky IB: Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 76: 977-983, 2009
8. De Boer I, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS: 25(OH)D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50: 69-77, 2007
9. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25(OH)D levels and risk of incident hypertension. Hypertension 49: 1063-1069, 2007
10. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB: Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29: 650-656, 2006 (Pubitemid 44115368)
11. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72: 1004-1013, 2007
12. Kilickesmez KO, Abaci O, Okcun B, Kocas C, Baskurt M, Arat A, Ersanli M, Gurmen T: Chronic kidney disease as a predictor of coronary lesion morphology. Angiology 61: 344-349, 2010
13. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM: Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med 152: 307-314, 2010
14. Wang L, Manson JE, Song Y, Sesso HD: Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 152: 315-323, 2010
15. NKF/KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Available at: http://www.kidney.org/professionals/ KDOQI/guidelines-bone/index.htm. Accessed September 3, 2010
16. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76: S50-S99, 2009
17. Wells GA, Shea B, O'Connell D, Petersen J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada. Available at: http://www.ohri.ca/programs/ clinical-epidemiology/oxford.htm. Accessed September 3, 2010
18. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412, 1995
19. Courbebaisse M, Thervet E, Souberbielle JC, Zuber J, Eladari D, Martinez F, Mamzer-Bruneel MF, Urena P, Legendre C, Friedlander G, Prié D: Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 75: 646-651, 2009
20. Lopes MG, Pillar R, Rocha L, Canziani EM, Carvalho A, Draibe S, Cuppari L: Effect of cholecalciferol supplementation on mineral metabolism parameters in CKD patients with vitamin D deficiency [Abstract]. J Am Soc Nephrol 20: 262A, 2009
21. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13, 2005
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 327: 557-560, 2003
23. Oksa A, Spustová V, Krivosíková Z, Gazdíková K, Fedelesová V, Lajdová I, Stefíková K, Bernasovská G, Zilinská Z, Dzúrik R: Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 31: 322-329, 2008
24. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V: Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study. Endocr Pract 14: 10-17, 2008
25. Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H: Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 30: 407-410, 2008
26. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D: A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 79: 108-115, 2005
27. Seibert E, Ulrich C, Seiler S, Heine GH, Kohler H, Girndt M: De novo cholecalciferol substitution in HD patients: A randomized, double-blind, placebo-controlled clinical trial [Abstract]. J Am Soc Nephrol 18: 727A, 2007
28. Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ: Changes in serum 25(OH)D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 50: 59-68, 2007
29. Bagnis C, Dutto F, Gabella P, Vitale C, D'Ella P, Marangella M, Ramello A: Biochemical and hormonal short term effects of 25 hydroxyvitamin D3 in patients on continuous peritoneal dialysis. Ital J Min Electrol Metabol 12: 73-76, 1998
30. Blair D, Byham-Gray L, Lewis E, McCaffrey S: Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 18: 375-382, 2008
31. Bouchard J, Ouimet D, Vallée M, Leblanc M, Pichette V: Effect of vitamin D supplementation on calcidiol and parathyroid hormone levels. Perit Dial Int 28: 565, 2008
32. DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH: Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25(OH)D in chronic kidney disease. Nephrology (Carlton) 11: 555-559, 2006
33. Jean G, Souberbielle JC, Chazot C: Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant 24: 3799-3805, 2009
34. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105: 132-138, 2007
35. Shah N, Bernardini J, Piraino B: Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 25: 362-366, 2005
36. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23: 4016-4020, 2008
37. Zisman AL, Hristova M, Ho LT, Sprague SM: Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 36-43, 2007
38. Balon BP, Jakopin E, Bevc S, Knehtl M, Gorenjak M: High-dose cholecalciferol supplementation for vitamin D deficiency in haemodialysis patients [Abstract]. World Congress of Nephrology, 2009. Available at:http://www.abstracts2view.com/wcn/view.php?nu=WCN09L-1185. Accessed September 3, 2010
39. Finn WF: Effect of ergocalciferol on calcium and 1,25-dihydroxyvitamn D levels in chronic kidney disease patients [Abstract]. J Am Soc Nephrol 18: 529A-530A, 2007
40. Matias P, Jorge C, Ferreira C: Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 5: 905-911, 2010
41. Pesenson A, Leca N, Szpiro AA, Kendrick EA, Davis CL: Effect of vitamin D supplementation with ergocalciferol in kidney transplantation [Abstract]. J Am Soc Nephrol 18: 31A, 2007
42. Shannon YM, Khambati N, Ho LT: Effects of ergocalciferol on ESA requirements in nondialysis CKD patients [Abstract]. J Am Soc Nephrol 18: 938A, 2007
43. Kestenbaum B, Belozeroff V: Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest 37: 607-622, 2007
44. Gutiérrez OM, Isakova T, Andress DL, Levin A, Wolf M: Prevalence and severity of disordered mineral metabolism in blacks with chronic kidney disease. Kidney Int 73: 956-962, 2008
45. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K: Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: 1144-1151, 2008
46. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
47. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Met 19: 429-435, 2004
48. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M: Posttransplant hypophosphatemia: Tertiary hyper-phosphotinism? Kidney Int 70: 1486-1494, 2006
49. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 4: CD008175, 2009
50. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF: Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 4: CD005633, 2009
51. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z: A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 5: 299-306, 2010
52. Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR: Serum 25(OH)D concentrations and risk for hip fractures. Ann Intern Med 149: 242-250, 2008
53. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J: Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148: 197-213, 2008
54. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
55. Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL: Vitamins K and D status in stages 3 to 5 chronic kidney disease. Clin J Am Soc Nephrol 5: 590-597, 2010
56. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N: Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am J Kidney Dis 54: 647-665, 2009
57. Agarwal R: Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 4: 1523-1528, 2009